(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Cardiopatía hipertensiva > DA - CIMA - Cardiovasculares - Cardiopatía hipertensiva - Artículos de Revista >

Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease
Autor(es) : Lopez, B. (Begoña)
Gonzalez, A. (Arantxa)
Varo, N. (Nerea)
Laviades, C. (Concepción)
Querejeta, R. (Ramón)
Diez, J. (Javier)
Palabras clave : Collagen
Hypertension, essential
Myocardium
Remodeling
Renin-angiotensin system
Fecha incorporación: 2001
Editorial : American Heart Association
Versión del editor: http://dx.doi.org/10.1161/​hy1101.098549
ISSN: 0194-911X
Cita: Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease. Hypertension 2001 Nov;38(5):1222-1226.
Resumen
Fibrous tissue accumulation is an integral feature of the adverse structural remodeling of cardiac tissue seen with hypertensive heart disease. Given the importance of fibrous tissue in leading to myocardial dysfunction and failure, noninvasive monitoring of myocardial fibrosis by use of serological markers of collagen turnover could prove a clinically useful tool, particularly given the potential for cardioprotective and cardioreparative pharmacological strategies. An emerging experimental and clinical experience holds promise for the use of radioimmunoassays of various serological markers of fibrillar collagen type I and type III turnover in arterial hypertension. More specifically, the measurement of serum concentrations of procollagen type I C-terminal propeptide (a peptide that is cleaved from procollagen type I during the synthesis of fibril-forming collagen type I) may provide indirect diagnostic information on both the extent of myocardial fibrosis and the ability of antihypertensive treatment to diminish collagen type I synthesis and reduce myocardial fibrosis. This approach represents an exciting and innovative strategy, and available data set the stage for larger trials, in which noninvasive measures of fibrosis in hypertensive heart disease could prove useful.
Enlace permanente: http://hdl.handle.net/10171/19910
Aparece en las colecciones: DA - CIMA - Cardiovasculares - Cardiopatía hipertensiva - Artículos de Revista

Ficheros en este registro:
Fichero:  Hypertension 2001;38;1222-1226.pdf
Descripción: 
Tamaño:  732,5 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.